tiprankstipranks
COSMOS Pharmaceutical Corporation (JP:3349)
TSE/TYO:3349
Japanese Market
Holding JP:3349?
Track your performance easily

COSMOS Pharmaceutical Corporation (3349) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

3349 Analyst Ratings

Moderate Buy
5Ratings
2 Buy
3 Hold
0 Sell
Based on 5 analysts giving stock ratings to
COSMOS
Pharmaceutical Corporation
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

3349 Stock 12 Month Forecast

Average Price Target

¥8,042.00
▲(25.54% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for COSMOS Pharmaceutical Corporation in the last 3 months. The average price target is ¥8,042.00 with a high forecast of ¥9,700.00 and a low forecast of ¥7,000.00. The average price target represents a 25.54% change from the last price of ¥6,406.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6315":"¥6,315","8008":"¥8,008","9701":"¥9,701","7161.5":"¥7,161.5","8854.5":"¥8,854.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8042,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6315,7161.5,8008,8854.5,9701],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7486,7656.307692307692,7826.615384615385,7996.923076923077,8167.2307692307695,8337.538461538461,8507.846153846154,8678.153846153846,8848.461538461539,9018.76923076923,9189.076923076924,9359.384615384615,9529.692307692309,{"y":9700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7486,7528.7692307692305,7571.538461538462,7614.307692307692,7657.076923076923,7699.846153846154,7742.615384615385,7785.384615384615,7828.153846153846,7870.923076923077,7913.692307692308,7956.461538461538,7999.2307692307695,{"y":8042,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7486,7448.615384615385,7411.2307692307695,7373.846153846154,7336.461538461538,7299.076923076923,7261.692307692308,7224.307692307692,7186.923076923077,7149.538461538462,7112.153846153846,7074.7692307692305,7037.384615384615,{"y":7000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8068.09,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7907.07,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7176.31,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6886.49,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7215.95,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6316.49,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6445.9,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6878.95,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7065.11,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7169.64,"date":1725580800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7434.44,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7092.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7486,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥9,700Average Price Target¥8,042Lowest Price Target¥7,000
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any

Best Analysts Covering COSMOS Pharmaceutical Corporation

Which Analyst Should I Follow If I Want to Buy JP:3349 and Sell After:
1 Month
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-3.40%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -3.40% per trade.
3 Months
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-10.95%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -10.95% per trade.
1 Year
Success Rate
0/2 ratings generated profit
0%
Average Return
-10.95%
reiterated a buy rating last month
Copying Takashi Yanahira's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.95% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-10.95%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -10.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3349 Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
0
0
0
0
Buy
0
2
3
3
Hold
2
3
3
2
Sell
1
1
1
0
Strong Sell
0
0
0
0
total
3
6
7
5
In the current month, 3349 has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 3349 average Analyst price target in the past 3 months is ¥8,042.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

3349 Financial Forecast

3349 Earnings Forecast

Next quarter’s earnings estimate for 3349 is ¥64.02 with a range of ¥55.60 to ¥71.39. The previous quarter’s EPS was ¥102.74. 3349 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.34% of the time in the same period. In the last calendar year 3349 has Outperformed its overall industry.
Next quarter’s earnings estimate for 3349 is ¥64.02 with a range of ¥55.60 to ¥71.39. The previous quarter’s EPS was ¥102.74. 3349 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.34% of the time in the same period. In the last calendar year 3349 has Outperformed its overall industry.

3349 Sales Forecast

Next quarter’s sales forecast for 3349 is ¥246.51B with a range of ¥242.22B to ¥253.16B. The previous quarter’s sales results were ¥261.84B. 3349 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.64% of the time in the same period. In the last calendar year 3349 has Outperformed its overall industry.
Next quarter’s sales forecast for 3349 is ¥246.51B with a range of ¥242.22B to ¥253.16B. The previous quarter’s sales results were ¥261.84B. 3349 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.64% of the time in the same period. In the last calendar year 3349 has Outperformed its overall industry.

3349 Stock Forecast FAQ

What is JP:3349’s average 12-month price target, according to analysts?
Based on analyst ratings, COSMOS Pharmaceutical Corporation’s 12-month average price target is ¥8,042.00.
    What is JP:3349’s upside potential, based on the analysts’ average price target?
    COSMOS Pharmaceutical Corporation has 25.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is COSMOS Pharmaceutical Corporation a Buy, Sell or Hold?
          COSMOS Pharmaceutical Corporation has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
            What is COSMOS Pharmaceutical Corporation’s share price target?
            The average share price target for COSMOS Pharmaceutical Corporation is ¥8,042.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥9,700.00 ,and the lowest forecast is ¥7,000.00. The average share price target represents 25.54% Increase from the current price of ¥6,406.
              What do analysts say about COSMOS Pharmaceutical Corporation?
              COSMOS Pharmaceutical Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of COSMOS Pharmaceutical Corporation?
                To buy shares of JP:3349, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis